Sandoz launches US Copaxone 40mg rival

Sandoz has received approval for and launched its Glatopa (glatiramer acetate) 40mg/ml rival to Teva’s higher-strength thrice-weekly Copaxone multiple-sclerosis treatment. Developed in collaboration with Momenta, the 40mg version of Glatopa – which accompanies the 20mg strength launched by Sandoz in June 2015 (Generics bulletin, 26 June 2015, page 1) – had seen its approval held up by manufacturing issues at a facility operated by fill-finish partner Pfizer.